SCHEMBL13095459

SCHEMBL13095459

Cc1nc([C@@H](C)NC(=O)c2cc(-c3ccc(F)cc3F)cc(C(O)C(F)F)c2)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.43
CNR2 P34972 2/20 0.39
GABRA5 P31644 1/20 0.37
WDR5 P61964 5/20 0.37
CTSA P10619 1/20 0.36
ROCK2 O75116 4/20 0.35
ROCK1 Q13464 4/20 0.35
BDKRB1 P46663 1/20 0.35
RPS6KA5 O75582 1/20 0.35
MAP4K4 O95819 1/20 0.35
PRKCG P05129 1/20 0.35
CDK1 P06493 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
CDK2 P24941 1/20 0.35
MAPK1 P28482 1/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35
FLT4 P35916 1/20 0.35
GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092754 0.89 DGAT2 (0.42) DGAT2CNR2GABRA5WDR5CTSA
SCHEMBL13104931 0.89 DGAT2 (0.44) DGAT2CNR2GABRA5WDR5CTSA
SCHEMBL3070727 0.86 WDR5 (0.38) DGAT2GABRA5WDR5CTSAROCK2
SCHEMBL21048472 0.86 WDR5 (0.38) DGAT2GABRA5WDR5CTSAROCK2
SCHEMBL13095460 0.85 NR1I2 (0.47) DGAT2CNR2GABRA5ROCK2PRKACA
SCHEMBL13095449 0.79 P2RX3 (0.43) DGAT2CNR2GABRA5BDKRB1
SCHEMBL21091768 0.77 AKR1C3 (0.43)
SCHEMBL13104922 0.75 GABRA5 (0.39) DGAT2GABRA5WDR5CTSAROCK2
SCHEMBL13092739 0.75 KCNT1 (0.41) DGAT2GABRA5WDR5
SCHEMBL13092766 0.74 NR1I2 (0.48) DGAT2CNR2GABRA5ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247401-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2012-08-21 US disclosed
US-8247401-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2012-08-21 US disclosed
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 DGAT2 3948/4885CNR2 48/4885GABRA5 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.